Skip to main content

Table 3 ERCC2 Asp312Asn, ERCC2 Lys751Gln polymorphisms and potential breast cancer risk factors

From: DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk

  Nonsmokers Smokers
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn         
Asp/Asp 283 (45) 299 (47) 1.00 (reference)   102 (42) 159 (44) 1.00 (reference)  
Asp/Asn 258 (41) 270 (43) 1.01 (0.80–1.28)   111 (46) 146 (41) 1.19 (0.83–1.68)  
Asn/Asn 85 (14) 64 (10) 1.4 (0.98–2.02) 0.16 29 (12) 54 (15) 0.84 (0.50–1.40) 0.36
  No HRT* users HRT users
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn         
Asp/Asp 175 (46) 137 (48) 1.00 (reference)   75 (40) 216 (47) 1.00 (reference)  
Asp/Asn 152 (40) 119 (41) 1.00 (0.72–1.39)   92 (49) 191 (42) 1.39 (0.97–1.99)  
Asn/Asn 54 (14) 31 (11) 1.36 (0.83–2.23) 0.44 19 (10) 50 (11) 1.09 (0.61–1.97) 0.20
  No OC** users OC users
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn         
Asp/Asp 240 (46) 215 (50) 1.00 (reference)   143 (42) 243 (43) 1.00 (reference)  
Asp/Asn 208 (40) 176 (41) 1.06 (0.81–1.39)   161 (47) 242 (43) 1.13 (0.85–1.51)  
Asn/Asn 74 (14) 40 (9) 1.66 (1.08–2.53) 0.061 40 (12) 78 (14) 0.87 (0.56–1.34) 0.44
ERCC2 Lys751Gln         
Lys/Lys 79 (15) 39 (9) 1.00 (reference)   38 (11) 80 (14) 1.00 (reference)  
Lys/Gln 223 (43) 198 (46) 0.56 (0.36–0.85)   181 (52) 248 (44) 1.54 (1.00–2.36)  
Gln/Gln 222 (42) 195 (45) 0.56 (0.37–0.86) 0.018 127 (37) 235 (42) 1.14 (0.73–1.77) 0.044
  Age at first OC use ≤ 23 years Age at first OC > 23 years
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Lys751Gln         
Lys/Lys 23 (14) 46 (15) 1.00 (reference)   15 (8) 34 (13) 1.00 (reference)  
Lys/Gln 80 (50) 145 (47) 1.10 (0.62–1.95)   101 (55) 103 (40) 2.22 (1.15–4.29)  
Gln/Gln 58 (36) 115 (38) 1.01 (0.56–1.82) 0.89 69 (37) 120 (47) 1.3 (0.66–2.56) 0.008
  Waist-to-hip ratio = 0.85 Waist-to-hip ratio > 0.85
Genotype Cases (%) Controls (%) OR (CI 95%) P value Cases (%) Controls (%) OR (CI 95%) P value
ERCC2 Asp312Asn         
Asp/Asp 252 (46) 356 (46) 1.00 (reference)   151 (42) 102 (48) 1.00 (reference)  
Asp/Asn 234 (43) 326 (42) 1.01 (0.80–1.28)   149 (42) 92 (43) 1.09 (0.76–1.57)  
Asn/Asn 60 (11) 98 (13) 0.86 (0.60–1.24) 0.68 58 (16) 20 (9) 1.96 (1.12–3.43) 0.06
  1. * HRT = Hormone Replacement Therapy
  2. ** OC = Oral Contraceptive